Table 1.
Participant characteristics at baseline
| Participants with weak-normal SOC (n = 125) | Participants with strong SOC (n = 81) | ||
|---|---|---|---|
| Mean ± SD | Mean ± SD | p valuea | |
| Age (years) | 52.6 ± 10.6 | 54.3 ± 9.0 | 0.23 |
| Body weight (kg) | 68.9 ± 11.1 | 67.8 ± 12.9 | 0.52 |
| Height (cm) | 165.4 ± 7.1 | 166.4 ± 6.0 | 0.30 |
| BMI (kg/m2) | 25.2 ± 4.0 | 24.5 ± 4.7 | 0.24 |
| Symptom burden | 0.9 ± 0.7 | 0.6 ± 0.6 | < 0.01 |
| Global HRQoL (QLQ-C30) | 62.1 ± 22.4 | 72.4 ± 22.2 | < 0.01 |
| Fatigue | 3.0 ± 3.0 | 1.8 ± 2.6 | < 0.01 |
| n (%) | n (%) | ||
| Married or partnered | 65 (52.0) | 57 (70.4) | 0.09 |
| Education level completed | 0.01 | ||
| Primary school | 28 (22.4) | 5 (6.2) | |
| Secondary school | 18 (14.4) | 16 (19.8) | |
| Tertiary education | 72 (57.6) | 59 (72.8) | |
| Current smoker | 7 (5.6) | 3 (3.7) | 0.58 |
| Menopausal status | 0.52 | ||
| Premenopausal | 48 (38.4) | 36 (44.4) | |
| Postmenopausal | 76 (60.8) | 45 (55.6) | |
| Tumour profile | 0.04 | ||
| Triple negative | 25 (20.0) | 4 (4.9) | |
| HER2+, ER+, PR+ | 12 (9.6) | 13 (16.0) | |
| HER2+, ER-, PR- | 9 (7.2) | 5 (6.2) | |
| HER2-, ER+, PR+ | 61 (48.8) | 45 (55.6) | |
| HER2-, ER+, PR- | 12 (9.6) | 8 (9.9) | |
| HER2+, ER+, PR- | 6 (4.8) | 4 (4.9) | |
| HER2-, ER-, PR+ | 0 (0.0) | 2 (2.5) | |
| Chemotherapy regimen | 0.60 | ||
| Anthracycline | 46 (36.8) | 35 (43.2) | |
| Taxane | 2 (1.6) | 4 (4.9) | |
| Anthracycline + Taxane | 48 (38.4) | 25 (30.9) | |
| Anthracycline + Taxane + Herceptin | 28 (22.4) | 16 (19.8) | |
| Anthracycline + Herceptin | 1 (0.8) | 1 (1.2) | |
| Group allocation | 0.20 | ||
| RT-HIIT | 41 (32.8) | 33 (40.7) | |
| AT-HIIT | 42 (33.6) | 30 (37.0) | |
| UC | 42 (33.6) | 18 (22.2) |